Superworth

QuidelOrtho PE ratio QDEL

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Oct 23, 2026
n/m
losses over the last year
Last meaningful
247×
Feb 2024
Earnings per share, 12 months
−$15.41
to Jun 28, 2026
Share price
$13.73
Oct 23, 2026
Peer median
60.4×

QuidelOrtho has no meaningful PE ratio today: it lost $15.41 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Feb 2024, at 247×.

It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.

Earnings per share over time

A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$16.66n/a
FY2024−$30.64n/a
FY2023−$0.16−101%
FY2022$12.40−24%
FY2021$16.32n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.36n/a−$15.41
Q1 FY26−$1.35n/a−$17.82
Q4 FY25−$1.92n/a−$16.66
Q3 FY25−$10.78n/a−$17.38
Q2 FY25−$3.77n/a−$6.90
Q1 FY25−$0.19n/a−$5.33
Q4 FY24−$2.64−2740%−$30.64
Q3 FY24−$0.30n/a−$27.90
Q2 FY24−$2.20n/a−$27.79
Q1 FY24−$25.50−3593%−$26.39
Q4 FY23$0.10−78%−$0.16
Q3 FY23−$0.19−168%$0.19

Against its peers

Companies in Medical - Diagnostics & Research nearest QuidelOrtho's size, closest first, today.

CompanyPE ratio
QDELQuidelOrthon/m
NRCNRC Health87.7×
CDNACareDx33.4×
VCYTVeracyte34.2×
BLLNBillionToOne166×
LNTHLantheus24.2×
CAICaris Life Sciences86.5×
Peer median60.4×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on QuidelOrtho

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.